Objectives: This systematic review aimed to evaluate the evidence for air and surface contamination of workplace environments with SARS-CoV-2 RNA and the quality of the methods used to identify actions necessary to improve the quality of the data.

Methods: We searched Web of Science and Google Scholar until 24 December 2020 for relevant articles and extracted data on methodology and results.

Results: The vast majority of data come from healthcare settings, with typically around 6% of samples having detectable concentrations of SARS-CoV-2 RNA and almost none of the samples collected had viable virus. There were a wide variety of methods used to measure airborne virus, although surface sampling was generally undertaken using nylon flocked swabs. Overall, the quality of the measurements was poor. Only a small number of studies reported the airborne concentration of SARS-CoV-2 virus RNA, mostly just reporting the detectable concentration values without reference to the detection limit. Imputing the geometric mean air concentration assuming the limit of detection was the lowest reported value, suggests typical concentrations in healthcare settings may be around 0.01 SARS-CoV-2 virus RNA copies m-3. Data on surface virus loading per unit area were mostly unavailable.

Conclusions: The reliability of the reported data is uncertain. The methods used for measuring SARS-CoV-2 and other respiratory viruses in work environments should be standardized to facilitate more consistent interpretation of contamination and to help reliably estimate worker exposure.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8385829PMC
http://dx.doi.org/10.1093/annweh/wxab026DOI Listing

Publication Analysis

Top Keywords

sars-cov-2 virus
12
systematic review
8
sars-cov-2 rna
8
healthcare settings
8
virus rna
8
sars-cov-2
6
virus
6
contamination air
4
air surfaces
4
surfaces workplaces
4

Similar Publications

Severity and Long-Term Mortality of COVID-19, Influenza, and Respiratory Syncytial Virus.

JAMA Intern Med

January 2025

Research and Development, Veterans Affairs Puget Sound Health Care System, Seattle, Washington.

Importance: SARS-CoV-2, influenza, and respiratory syncytial virus (RSV) contribute to many hospitalizations and deaths each year. Understanding relative disease severity can help to inform vaccination guidance.

Objective: To compare disease severity of COVID-19, influenza, and RSV among US veterans.

View Article and Find Full Text PDF

A significant proportion of patients who have recovered from COVID-19 suffer from persistent symptoms, referred to as "post-acute sequelae of SARS-CoV-2 infection (PASC)". Abnormal brain intrinsic activity has been observed in PASC patients, but the patterns of frequency-dependent intrinsic activity in the PASC and non-PASC (recovered COVID-19 patients without persistent symptoms) groups and their association with neuropsychiatric sequelae remain unclear in PASC. Twenty-nine PASC patients, 27 non-PASC subjects, and 31 healthy controls (HCs) were recruited.

View Article and Find Full Text PDF

Viremia defined as detectable SARS-CoV-2 RNA in the blood is a potential marker of disease severity and prognosis in COVID-19 patients. Here, we determined the frequency of viremia in serum of two independent COVID-19 patient cohorts within the German National Pandemic Cohort Network (German: tionales andemie horten etzwerk, NAPKON) with diagnostic RT-PCR against SARS-CoV-2. A cross-sectional cohort with 1,122 COVID-19 patients (German: , SUEP) and 299 patients recruited in a high-resolution platform with patients at high risk to develop severe courses (German: , HAP) were tested for viremia.

View Article and Find Full Text PDF

Low Neutralization of SARS-CoV-2 Omicron BA5248, XBB15 and JN1 by Homologous Booster and Breakthrough Infection.

J Med Virol

February 2025

Key Laboratory of Artificial Organs and Computational Medicine in Zhejiang Province, Shulan International Medical College, Zhejiang Shuren University, Hangzhou, Zhejiang, P. R. China.

Immunity against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) can be induced through either infection with the virus or vaccination, providing protection against reinfection or reducing the risk of severe clinical outcomes. In this study, we recruited 172 volunteers who received different vaccination regimens, including 124 individuals who had recovered from breakthrough infections caused by the Omicron variant (27 with 2 doses, 49 with 3 doses, and 48 with 4 doses) and 48 healthy donors who did not experience breakthrough infections (all of whom received a fourth dose during the infection wave). We measured neutralizing antibody levels against Omicron BA.

View Article and Find Full Text PDF

Safety and immunogenicity of Ad26.COV2.S in adolescents: Phase 2 randomized clinical trial.

Hum Vaccin Immunother

December 2025

Crucell Integration, Janssen Research and Development, Beerse, Belgium.

We conducted a randomized, Phase 2 trial to assess the safety and humoral immunogenicity of reduced doses/dose volume of the standard dose of Ad26.COV2.S COVID-19 vaccine (5 × 10 viral particles [vp]) in healthy adolescents aged 12-17 years.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!